Home / Health / FDA Extends Review of Experimental Hemophilia Drug
FDA Extends Review of Experimental Hemophilia Drug
3 Oct
Summary
- FDA review period for Novo Nordisk's hemophilia A drug extended.
- Review extension is due to ongoing remediation at a facility.
- The Danish drugmaker announced the review extension on Friday.
The U.S. Food and Drug Administration (FDA) has extended its review period for an experimental hemophilia A drug developed by Novo Nordisk. The decision was announced by the Danish drugmaker on Friday, October 2nd, 2026.
This extension is a direct result of ongoing remediation work required at one of the drug's manufacturing facilities. The FDA's scrutiny emphasizes the critical nature of manufacturing processes in drug approvals.
The extended review timeline may affect the anticipated market entry of Novo Nordisk's hemophilia A treatment.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
